{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:08:36Z","timestamp":1772294916951,"version":"3.50.1"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>T-cell engager therapies for the management of relapsed\/refractory (R\/R) multiple myeloma (MM) may lead to neutropenia with or without associated infections, which can limit treatment and efficacy. We present a case of a patient with penta-class R\/R MM who, while receiving teclistamab, developed persistent severe to moderate neutropenia with associated infections. A review of her bone marrow confirmed the eradication of the malignant plasma cells, but flow cytometry identified an increase in T-cell large granular lymphocytes (T-LGLs). Upon further analysis, T-LGLs were found to be reactive and non-clonal, ruling out secondary T-LGL leukemia. This case describes the evolving peripheral blood cell counts, bone marrow composition, and radiologic findings due to the activation of the patient\u2019s immune system before, during, and after treatment with teclistamab. To our knowledge, this is the first reported potential association of T-LGL activation with teclistamab treatment.<\/jats:p>","DOI":"10.3389\/fonc.2025.1630929","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:22Z","timestamp":1754453542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed\/refractory multiple myeloma receiving teclistamab"],"prefix":"10.3389","volume":"15","author":[{"given":"Erin A.","family":"Dean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Wingard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","unstructured":"NCCN.org\n          Multiple Myeloma. Version 1.2026\u2014 June 24, 2025. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology"},{"key":"B2","unstructured":"label"},{"key":"B3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: A real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5045\/br.2023.2023037","article-title":"T-large granular lymphocytic leukemia","volume":"58","author":"Park","year":"2023","journal-title":"Blood Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.805449","article-title":"T-cell large granular lymphocyte leukemia: an interdisciplinary issue","volume":"12","author":"Schreiber","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jtct.2020.12.008","article-title":"Large granular lymphocytosis with cytopenias after allogeneic blood or marrow transplantation: clinical characteristics and response to immunosuppressive therapy","volume":"27","author":"Messmer","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1016\/j.jtct.2023.12.228","article-title":"T-cell large granular lymphocyte population involving chimeric antigen receptor-modified T (CAR T) cells in patients with cytopenia after CD19-targeted CAR T-cell therapy: case series","volume":"30","author":"Albittar","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004588","article-title":"2-[18F] FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma","volume":"48","author":"Jamet","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1630929\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:26Z","timestamp":1754453546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1630929\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":13,"alternative-id":["10.3389\/fonc.2025.1630929"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1630929","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1630929"}}